RESNATI, CHIARA
RESNATI, CHIARA
Dipartimento di Scienze Biomediche e Cliniche
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens
2021 D. Cattaneo, M. Fusi, V. Micheli, C. Resnati, P. Meraviglia, M.V. Cossu, S. Vimercati, G.C. Bisinella, S. Baldelli, S. Antinori, C. Gervasoni
IMPATTO DI COBICISTAT SU DURATA ETOLLERABILITA¿ DI REGIMI ANTIRETROVIRALICONTENENTI TENOFOVIR DIPROXIL FUMARATO
2018 C. Resnati
Correlation between inner retinal layer thickness and cognitive function in HIV: New insights from an exploratory study
2018 A. Invernizzi, A. Acquistapace, S. Bochicchio, C. Resnati, S. Rusconi, M. Ferrari, V. Leta, S. Pomati, A. Klistorner, P. Mccluskey, G. Staurenghi, A. Riva
Dolutegravir and metformin : a clinically relevant or just a pharmacokinetic interaction?
2018 D. Cattaneo, C. Resnati, G. Rizzardini, C. Gervasoni
Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients : Potential implications for clinical practice
2018 D. Cattaneo, S. Baldelli, C. Resnati, A. Giacomelli, P. Meraviglia, D. Minisci, N. Astuti, L. Ridolfo Anna, V. De Socio Giuseppe, E. Clementi, M. Galli, C. Gervasoni
Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF
2018 D. Cattaneo, D. Minisci, S. Baldelli, C. Mazzali, A. Giacomelli, L. Milazzo, P. Meraviglia, C. Resnati, G. Rizzardini, E. Clementi, M. Galli, C. Gervasoni
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
2018 L. Peters, K. Laut, C. Resnati, S. Del Campo, C. Leen, K. Falconer, T. Trofimova, D. Paduta, J. Gatell, A. Rauch, K. Lacombe, P. Domingo, N. Chkhartishvili, R. Zangerle, R. Matulionyte, V. Mitsura, T. Benfield, K. Zilmer, I. Khromova, J. Lundgren, J. Rockstroh, A. Mocroft, G. EuroSIDA Study
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration
2018 C. Gervasoni, C. Resnati, T. Formenti, A. Fossati, D. Minisci, P. Meraviglia, D. Cattaneo
Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons
2017 D. Cattaneo, A. Fossati, C. Resnati, M. Galli, C. Gervasoni
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir
2017 C. Gervasoni, D. Cattaneo, C. Resnati, D. Pezzani, A. Riva
Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan Italy
2017 A.L. Ridolfo, L. Oreni, P. Vassalini, C. Resnati, G. Bozzi, L. Milazzo, S. Antinori, S. Rusconi, M. Galli
Pharmacogenetics-based optimisation of atazanavir treatment : potential role of new genetic predictors
2017 F.S. Falvella, E. Ricci, S. Cheli, C. Resnati, V. Cozzi, D. Cattaneo, C. Gervasoni, E.G.I. Clementi, M. Galli, A. Riva
Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
2017 A. Riva, A. Invernizzi, C. Resnati, V. Micheli, D. Cattaneo, C. Gervasoni
Abacavir-induced liver toxicity
2016 M.D. Pezzani, C. Resnati, V. Di Cristo, A. Riva, C. Gervasoni
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient
2016 D. Cattaneo, S. Sollima, N. Charbe, C. Resnati, E. Clementi, C. Gervasoni
Peripheral blood pre-erythroidal cells in HIV-1 infection
2015 M.S. Tarkowski, L. Ghita, E. Calvi, L. Milazzo, C. Gervasoni, C. Resnati, M. Mena, P. Castelli, M.P. Allegri, C. Atzori, I. Cetin, M. Galli, A. Riva
Analyses of Pre-erythroid cells in peripheral blood of patients with different progression of HIV infection
2015 M.S. Tarkowski, L. Ghita, L. Milazzo, E. Calvi, A.M. Peri, C. Resnati, C. Gervasoni, M. Galli, A. Riva
Prolonged inductive effect of rifampicin on linezolid exposure
2015 C. Gervasoni, F.R. Simonetti, C. Resnati, N. Charbe, E. Clementi, D. Cattaneo
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study
2015 D. Cattaneo, M.V. Cossu, S. Fucile, A. Riva, S. Baldelli, P. Meraviglia, S. Landonio, C. Impagnatiello, C. Resnati, M. Galli, E. Clementi, A. Capetti, G. Rizzardini, C. Gervasoni
Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy
2014 M. Franzetti, F. Adorni, L. Oreni, L. van Den Bogaart, C. Resnati, L. Milazzo, S. Antinori, M. Galli, A.L. Ridolfo